Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2017-03-772285 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study.
J Clin Med
December 2024
Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool L7 8YA, UK.
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia among adults, particularly in Western nations. The introduction of Bruton's tyrosine kinase (BTK) inhibitors as a treatment of CLL, namely, ibrutinib, which is a first-generation BTK inhibitor, has significantly improved the treatment landscape for CLL. However, ibrutinib has been associated with an increased risk of atrial fibrillation (AF) and hypertension.
View Article and Find Full Text PDFReal-World Evidence on Adverse Events and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukaemia in Spain Using Natural Language Processing: The SRealCLL Study.
Cancers (Basel)
November 2024
Haematology Department, Hospital Universitario de la Princesa, 28004 Madrid, Spain.
The SRealCLL study described the occurrence of adverse events (AEs) and healthcare resource utilization in patients with chronic lymphocytic leukaemia (CLL) using artificial intelligence in a real-world scenario in Spain. We collected real-world data on patients with CLL from seven Spanish hospitals between January 2016 and December 2018, focusing on their AE and healthcare service utilization. Data extraction from electronic health records of 385,904 patients was performed using the EHRead technology, which is based on natural language processing and machine learning.
View Article and Find Full Text PDFScedosporium Brain Abscess: A Rare and Fatal Drawback of Bruton Tyrosine Kinase Inhibitor Therapy.
J Hematol
October 2024
Department of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, 10043 Orbassano, Italy.
The patient described in this case report was admitted to the San Luigi Hospital in Turin for confusion, drowsiness, and buccal and eye deviation. An acute neurological disease was suspected. He was affected by chronic lymphocytic leukemia (CLL) on active treatment with the novel Bruton tyrosine kinase inhibitor (BTKi) acalabrutinib.
View Article and Find Full Text PDFComparing the Efficacy and Safety of First-Line Treatments for Chronic Lymphocytic Leukemia: A Network Meta-Analysis.
J Natl Cancer Inst
October 2024
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Article Synopsis
- The treatment approach for Chronic Lymphocytic Leukemia (CLL) is shifting from chemotherapy to chemo-free regimens, and this study utilizes frequentist network meta-analysis to compare various treatment options effectively.
- The analysis included 30 trials with 12,818 patients, focusing on first-line treatments and measuring outcomes like progression-free survival (PFS), minimal residual disease, and adverse events across different patient groups.
- Acalabrutinib showed generally better PFS in older patients and those with certain comorbidities, while other treatments had varying benefits and side effects, highlighting the importance of personalized treatment strategies based on individual patient characteristics.
Medical- and Implant-Related Complications Following Total Joint Arthroplasty in Patients Who Have Chronic Lymphocytic Leukemia.
J Arthroplasty
October 2024
Larkin Community Hospital, Department of Orthopaedic Surgery, South Miami, Florida; Hospital for Special Surgery, Department of Orthopaedic Surgery, West Palm Beach, Florida; Holy Cross Orthopedic Institute, Holy Cross Health, Fort Lauderdale, Florida.
Article Synopsis
- Chronic lymphocytic leukemia (CLL) significantly increases the risk of medical complications, particularly pneumonia and heart issues, in patients undergoing total knee arthroplasty (TKA) and total hip arthroplasty (THA).
- CLL patients experience longer hospital stays and a higher rate of readmission post-surgery compared to non-CLL patients, indicating greater overall healthcare utilization.
- The study suggests that orthopedic surgeons should factor in a patient's CLL status when advising on knee or hip replacement procedures to help minimize complications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!